Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.

Madhi SA, Koen A, Cutland CL, Jose L, Govender N, Wittke F, Olugbosi M, Sobanjo-Ter Meulen A, Baker S, Dull PM, Narasimhan V, Slobod K.

Clin Infect Dis. 2017 Nov 13;65(11):1897-1904. doi: 10.1093/cid/cix666.

2.

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.

Madhi SA, Cutland CL, Jose L, Koen A, Govender N, Wittke F, Olugbosi M, Meulen AS, Baker S, Dull PM, Narasimhan V, Slobod K.

Lancet Infect Dis. 2016 Aug;16(8):923-34. doi: 10.1016/S1473-3099(16)00152-3. Epub 2016 Apr 29.

PMID:
27139805
3.

Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial.

Donders GG, Halperin SA, Devlieger R, Baker S, Forte P, Wittke F, Slobod KS, Dull PM.

Obstet Gynecol. 2016 Feb;127(2):213-21. doi: 10.1097/AOG.0000000000001190.

PMID:
26942345
4.

Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.

Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambo D, Mboizi R, Koen A, Jose L, Olugbosi M, Wittke F, Slobod K, Dull PM.

Lancet Infect Dis. 2016 May;16(5):546-555. doi: 10.1016/S1473-3099(15)00484-3. Epub 2016 Feb 8.

5.

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.

Snape MD, Voysey M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Kieninger D, Prymula R, Dull PM, Kohl I, Barone M, Wang H, Toneatto D, Pollard AJ; European MenB Vaccine Study Group.

Pediatr Infect Dis J. 2016 Apr;35(4):e113-23. doi: 10.1097/INF.0000000000001056.

PMID:
26756390
6.

Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial.

Block SL, Shepard J, Garfield H, Xie F, Han L, Dull PM, Smolenov I.

Pediatr Infect Dis J. 2016 Feb;35(2):e48-59. doi: 10.1097/INF.0000000000000965.

PMID:
26479973
7.

Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.

Vesikari T, Prymula R, Merrall E, Kohl I, Toneatto D, Dull PM.

Vaccine. 2015 Jul 31;33(32):3850-8. doi: 10.1016/j.vaccine.2015.06.079. Epub 2015 Jun 30.

PMID:
26141011
8.

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.

Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Graña MG, Heijnen E, Smolenov I, Dull PM.

Hum Vaccin Immunother. 2015;11(6):1507-17. doi: 10.1080/21645515.2015.1029686.

9.

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu LM, Toneatto D, D'Agostino D, Dull PM, Pollard AJ.

CMAJ. 2015 Apr 21;187(7):E215-E223. doi: 10.1503/cmaj.141200. Epub 2015 Mar 23.

10.

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.

Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17.

PMID:
25795256
11.

Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.

Block SL, Christensen S, Verma B, Xie F, Keshavan P, Dull PM, Smolenov I.

Vaccine. 2015 Apr 27;33(18):2175-82. doi: 10.1016/j.vaccine.2015.02.049. Epub 2015 Mar 2.

PMID:
25744224
12.

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).

Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, Toneatto D.

Hum Vaccin Immunother. 2014;10(7):2005-14. doi: 10.4161/hv.29218.

13.

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).

Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM.

Hum Vaccin Immunother. 2014;10(7):1993-2004. doi: 10.4161/hv.28666.

14.

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.

Lee HJ, Chung MH, Kim WJ, Hong YJ, Choi KM, Lee J, Oh CE, Welsch JA, Kim KH, Hong KB, Dagnew AF, Bock H, Dull PM, Odrljin T.

Int J Infect Dis. 2014 Nov;28:204-10. doi: 10.1016/j.ijid.2014.06.008. Epub 2014 Oct 12.

15.

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.

Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R.

Lancet. 2014 Dec 13;384(9960):2123-31. doi: 10.1016/S0140-6736(14)60842-4. Epub 2014 Aug 18.

PMID:
25145775
16.

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.

Tregnaghi M, Lopez P, Stamboulian D, Graña G, Odrljin T, Bedell L, Dull PM.

Int J Infect Dis. 2014 Sep;26:22-30. doi: 10.1016/j.ijid.2014.03.1390. Epub 2014 Jun 26.

17.

Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.

Baxter R, Reisinger K, Block SL, Percell S, Odrljin T, Dull PM, Smolenov I.

Pediatr Infect Dis J. 2014 Nov;33(11):1169-76. doi: 10.1097/INF.0000000000000438.

PMID:
24911896
18.

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.

McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Houlden J, Voysey M, Toneatto D, Kitte C, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2014 Jul;33(7):760-6. doi: 10.1097/INF.0000000000000327.

PMID:
24722351
19.

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.

Abdelnour A, Silas PE, Lamas MR, Aragón CF, Chiu NC, Chiu CH, Acuña TH, Castrejón Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM.

Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4.

PMID:
24397906
20.

A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.

O'Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM.

Drugs. 2014 Jan;74(1):15-30. doi: 10.1007/s40265-013-0155-7. Review.

21.

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.

Nolan TM, Nissen MD, Naz A, Shepard J, Bedell L, Hohenboken M, Odrljin T, Dull PM.

Hum Vaccin Immunother. 2014;10(2):280-9. doi: 10.4161/hv.27051. Epub 2013 Nov 12.

22.

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.

Snape MD, Saroey P, John TM, Robinson H, Kelly S, Gossger N, Yu LM, Wang H, Toneatto D, Dull PM, Pollard AJ.

CMAJ. 2013 Oct 15;185(15):E715-24. doi: 10.1503/cmaj.130257. Epub 2013 Sep 23.

23.

Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.

Madhi SA, Dangor Z, Heath PT, Schrag S, Izu A, Sobanjo-Ter Meulen A, Dull PM.

Vaccine. 2013 Aug 28;31 Suppl 4:D52-7. doi: 10.1016/j.vaccine.2013.02.029. Review.

PMID:
23973347
24.

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.

Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, Yu LM, Kittel C, Toneatto D, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2013 Oct;32(10):1116-21. doi: 10.1097/INF.0b013e31829cfff2.

PMID:
23958808
25.

Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.

Santolaya ME, O'Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, Toneatto D, Graña G, Wang H, Dull PM.

Hum Vaccin Immunother. 2013 Nov;9(11):2304-10. Epub 2013 Jun 28.

26.

Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.

Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Kibwana E, Parks H, Ford K, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2013 Jul;32(7):768-76. doi: 10.1097/INF.0b013e318292f425.

PMID:
23538521
27.

Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.

Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM.

Pediatr Infect Dis J. 2013 Apr;32(4):e170-7. doi: 10.1097/INF.0b013e318279ac38.

PMID:
23114372
28.

Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.

Clarke ET, Williams NA, Dull PM, Findlow J, Borrow R, Finn A, Heyderman RS.

Mucosal Immunol. 2013 Mar;6(2):288-96. doi: 10.1038/mi.2012.70. Epub 2012 Jul 18.

PMID:
22806100
29.

Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.

Dull PM, McIntosh ED.

Vaccine. 2012 May 30;30 Suppl 2:B18-25. doi: 10.1016/j.vaccine.2012.01.062. Review.

PMID:
22607895
30.

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.

Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ.

Vaccine. 2012 Apr 16;30(18):2831-8. doi: 10.1016/j.vaccine.2012.02.046. Epub 2012 Mar 3.

PMID:
22394992
31.

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group.

Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Erratum in: Lancet. 2015 May 2;385(9979):1728.

PMID:
22260988
32.

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.

Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM.

Vaccine. 2010 Nov 23;28(50):7865-72. doi: 10.1016/j.vaccine.2010.09.092. Epub 2010 Oct 29.

33.

Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.

Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM.

Int J Infect Dis. 2010 Oct;14(10):e868-75. doi: 10.1016/j.ijid.2010.03.017. Epub 2010 Jul 22.

34.

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.

Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, Grunwald U, Bedell L, Anemona A, Dull PM.

Vaccine. 2010 Apr 19;28(18):3171-9. doi: 10.1016/j.vaccine.2010.02.045. Epub 2010 Feb 26.

PMID:
20189491
36.

Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.

Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM.

Vaccine. 2010 Jan 8;28(3):657-63. doi: 10.1016/j.vaccine.2009.10.104. Epub 2009 Nov 4.

PMID:
19895922
37.

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.

Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM.

Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.

38.

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages.

Bröker M, Dull PM, Rappuoli R, Costantino P.

Vaccine. 2009 Sep 18;27(41):5574-80. doi: 10.1016/j.vaccine.2009.07.036. Epub 2009 Jul 18. Review.

PMID:
19619500
39.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group.

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

PMID:
19476428
40.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
41.

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM.

Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237.

PMID:
19116603
42.

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

JAMA. 2008 Jan 9;299(2):173-84. doi: 10.1001/jama.2007.29-c. Erratum in: JAMA. 2011 Mar 16;305(11):1096.

PMID:
18182599
43.

Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj.

Dull PM, Abdelwahab J, Sacchi CT, Becker M, Noble CA, Barnett GA, Kaiser RM, Mayer LW, Whitney AM, Schmink S, Ajello GW, Dolan-Livengood J, Stephens DS, Cetron MS, Popovic T, Rosenstein NE.

J Infect Dis. 2005 Jan 1;191(1):33-9. Epub 2004 Nov 29.

PMID:
15593000
44.

Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, Steward-Clark E, Stamey KL, Schmidt DS, Stinson KW, Freeman AE, Elie CM, Martin SK, Greene C, Aubert RD, Glidewell J, Perkins BA, Ahmed R, Stephens DS.

J Infect Dis. 2004 Oct 1;190(7):1228-36. Epub 2004 Aug 30.

PMID:
15346332
45.

The etiology of febrile illness in adults presenting to Patan hospital in Kathmandu, Nepal.

Murdoch DR, Woods CW, Zimmerman MD, Dull PM, Belbase RH, Keenan AJ, Scott RM, Basnyat B, Archibald LK, Reller LB.

Am J Trop Med Hyg. 2004 Jun;70(6):670-5.

PMID:
15211012
46.

One-year health assessment of adult survivors of Bacillus anthracis infection.

Reissman DB, Whitney EA, Taylor TH Jr, Hayslett JA, Dull PM, Arias I, Ashford DA, Bresnitz EA, Tan C, Rosenstein N, Perkins BA.

JAMA. 2004 Apr 28;291(16):1994-8.

PMID:
15113818
47.

Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses.

Kuehnert MJ, Doyle TJ, Hill HA, Bridges CB, Jernigan JA, Dull PM, Reissman DB, Ashford DA, Jernigan DB.

Clin Infect Dis. 2003 Feb 1;36(3):328-36. Epub 2003 Jan 20.

PMID:
12539075
48.

Bacillus anthracis aerosolization associated with a contaminated mail sorting machine.

Dull PM, Wilson KE, Kournikakis B, Whitney EA, Boulet CA, Ho JY, Ogston J, Spence MR, McKenzie MM, Phelan MA, Popovic T, Ashford D.

Emerg Infect Dis. 2002 Oct;8(10):1044-7.

49.

First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001.

Traeger MS, Wiersma ST, Rosenstein NE, Malecki JM, Shepard CW, Raghunathan PL, Pillai SP, Popovic T, Quinn CP, Meyer RF, Zaki SR, Kumar S, Bruce SM, Sejvar JJ, Dull PM, Tierney BC, Jones JD, Perkins BA; Florida Investigation Team.

Emerg Infect Dis. 2002 Oct;8(10):1029-34.

Supplemental Content

Support Center